Swedish Drug Discovery and Development Pipeline 2020
| Reference number | |
| Coordinator | SwedenBIO Service AB |
| Funding from Vinnova | SEK 100 000 |
| Project duration | December 2019 - June 2020 |
| Status | Completed |
| Venture | 2017-01599-en |
Important results from the project
The purpose of the project was to map the pipeline of pharmaceutical projects Swedish life science companies have with the goal of visualizing the situation, development and trends in the industry. Only companies with R&D activities in Sweden were included. The focus was on qualitatively and quantitatively describing development projects in both discovery, preclinical and clinical I-III phases. A report was compiled by SwedenBIO where a comparison was also made with the previous years´ reports.
Expected long term effects
The Drug Discovery and Development Pipeline 2020 report was compiled by SwedenBIO. The report includes a company analysis, including the number of companies with both preclinical and clinical projects, number of employees, and hot-spots in Sweden. More than 500 participants participated in the release day on June 2, 2020. Participants were representatives from promotion organisations, life science companies, politicians, etc. The report will be used in marketing of Swedish life science both nationally and internationally by SwedenBIO, Business Sweden and the Business regions.
Approach and implementation
SwedenBIO performed an extensive search using information from different databases and previous years’ reports to identify companies active in the field of discovery and development of drugs for human use. National incubators, science parks and investment promotion agencies were also contacted to broaden the scope of the search. An on-line survey was prepared and during January-February 2020 we invited companies, via e-mail and newsletters, to participate in the survey. The data from the survey was collated and follow-up interviews were performed both by phone and e-mail.